Survival determinants in patients with advanced ovarian cancer

Stephen Maxted Ansell, B. L. Rapoport, G. Falkson, J. I. Raats, C. M. Moeken

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

An analysis was performed on 127 consecutive women with advanced measurable ovarian cancer to evaluate factors predicting for survival. All patients received cis-platinum-based chemotherapy as treatment for stage IIIB to stage IV disease. Eighteen clinical, radiological, and biochemical parameters were subjected to univariate and multivariate analyses. Recursive partitioning and amalgamation (RPA) was used to define prognostic subsets with different survival potentials. In the univariate analysis, factors that predicted for survival were weight loss, histology, stage, number of metastases, presence of ascites, size of the residual tumor, and rate of tumor response. When these significant variables were included in a Cox model, advanced stage of disease, histology other than adenoserous carcinoma, the presence of tumor bulk, and a slow rate of tumor response independently predicted a poorer survival. Using the three disease-related prognostic variables, a RPA model was derived and three groups were identified with median survival times of 76, 28, and 21 months, respectively (P = 0.001). The best survival time of 76 months was seen in patients with stage III, non- bulky, adenoserous ovarian carcinoma. It is concluded that the rate of tumor response is important in predicting the outcome of patients with ovarian cancer. Furthermore, the interactions between prognostic factors are emphasized by the RPA model and a subgroup of patients with a projected 10- year survival of 50% is identified.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalGynecologic Oncology
Volume50
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Survival
Neoplasms
Histology
Carcinoma
Residual Neoplasm
Proportional Hazards Models
Ascites
Cisplatin
Weight Loss
Multivariate Analysis
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Ansell, S. M., Rapoport, B. L., Falkson, G., Raats, J. I., & Moeken, C. M. (1993). Survival determinants in patients with advanced ovarian cancer. Gynecologic Oncology, 50(2), 215-220. https://doi.org/10.1006/gyno.1993.1195

Survival determinants in patients with advanced ovarian cancer. / Ansell, Stephen Maxted; Rapoport, B. L.; Falkson, G.; Raats, J. I.; Moeken, C. M.

In: Gynecologic Oncology, Vol. 50, No. 2, 1993, p. 215-220.

Research output: Contribution to journalArticle

Ansell, SM, Rapoport, BL, Falkson, G, Raats, JI & Moeken, CM 1993, 'Survival determinants in patients with advanced ovarian cancer', Gynecologic Oncology, vol. 50, no. 2, pp. 215-220. https://doi.org/10.1006/gyno.1993.1195
Ansell, Stephen Maxted ; Rapoport, B. L. ; Falkson, G. ; Raats, J. I. ; Moeken, C. M. / Survival determinants in patients with advanced ovarian cancer. In: Gynecologic Oncology. 1993 ; Vol. 50, No. 2. pp. 215-220.
@article{fd3da45a144748b99ca1dfdfb6f3701b,
title = "Survival determinants in patients with advanced ovarian cancer",
abstract = "An analysis was performed on 127 consecutive women with advanced measurable ovarian cancer to evaluate factors predicting for survival. All patients received cis-platinum-based chemotherapy as treatment for stage IIIB to stage IV disease. Eighteen clinical, radiological, and biochemical parameters were subjected to univariate and multivariate analyses. Recursive partitioning and amalgamation (RPA) was used to define prognostic subsets with different survival potentials. In the univariate analysis, factors that predicted for survival were weight loss, histology, stage, number of metastases, presence of ascites, size of the residual tumor, and rate of tumor response. When these significant variables were included in a Cox model, advanced stage of disease, histology other than adenoserous carcinoma, the presence of tumor bulk, and a slow rate of tumor response independently predicted a poorer survival. Using the three disease-related prognostic variables, a RPA model was derived and three groups were identified with median survival times of 76, 28, and 21 months, respectively (P = 0.001). The best survival time of 76 months was seen in patients with stage III, non- bulky, adenoserous ovarian carcinoma. It is concluded that the rate of tumor response is important in predicting the outcome of patients with ovarian cancer. Furthermore, the interactions between prognostic factors are emphasized by the RPA model and a subgroup of patients with a projected 10- year survival of 50{\%} is identified.",
author = "Ansell, {Stephen Maxted} and Rapoport, {B. L.} and G. Falkson and Raats, {J. I.} and Moeken, {C. M.}",
year = "1993",
doi = "10.1006/gyno.1993.1195",
language = "English (US)",
volume = "50",
pages = "215--220",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Survival determinants in patients with advanced ovarian cancer

AU - Ansell, Stephen Maxted

AU - Rapoport, B. L.

AU - Falkson, G.

AU - Raats, J. I.

AU - Moeken, C. M.

PY - 1993

Y1 - 1993

N2 - An analysis was performed on 127 consecutive women with advanced measurable ovarian cancer to evaluate factors predicting for survival. All patients received cis-platinum-based chemotherapy as treatment for stage IIIB to stage IV disease. Eighteen clinical, radiological, and biochemical parameters were subjected to univariate and multivariate analyses. Recursive partitioning and amalgamation (RPA) was used to define prognostic subsets with different survival potentials. In the univariate analysis, factors that predicted for survival were weight loss, histology, stage, number of metastases, presence of ascites, size of the residual tumor, and rate of tumor response. When these significant variables were included in a Cox model, advanced stage of disease, histology other than adenoserous carcinoma, the presence of tumor bulk, and a slow rate of tumor response independently predicted a poorer survival. Using the three disease-related prognostic variables, a RPA model was derived and three groups were identified with median survival times of 76, 28, and 21 months, respectively (P = 0.001). The best survival time of 76 months was seen in patients with stage III, non- bulky, adenoserous ovarian carcinoma. It is concluded that the rate of tumor response is important in predicting the outcome of patients with ovarian cancer. Furthermore, the interactions between prognostic factors are emphasized by the RPA model and a subgroup of patients with a projected 10- year survival of 50% is identified.

AB - An analysis was performed on 127 consecutive women with advanced measurable ovarian cancer to evaluate factors predicting for survival. All patients received cis-platinum-based chemotherapy as treatment for stage IIIB to stage IV disease. Eighteen clinical, radiological, and biochemical parameters were subjected to univariate and multivariate analyses. Recursive partitioning and amalgamation (RPA) was used to define prognostic subsets with different survival potentials. In the univariate analysis, factors that predicted for survival were weight loss, histology, stage, number of metastases, presence of ascites, size of the residual tumor, and rate of tumor response. When these significant variables were included in a Cox model, advanced stage of disease, histology other than adenoserous carcinoma, the presence of tumor bulk, and a slow rate of tumor response independently predicted a poorer survival. Using the three disease-related prognostic variables, a RPA model was derived and three groups were identified with median survival times of 76, 28, and 21 months, respectively (P = 0.001). The best survival time of 76 months was seen in patients with stage III, non- bulky, adenoserous ovarian carcinoma. It is concluded that the rate of tumor response is important in predicting the outcome of patients with ovarian cancer. Furthermore, the interactions between prognostic factors are emphasized by the RPA model and a subgroup of patients with a projected 10- year survival of 50% is identified.

UR - http://www.scopus.com/inward/record.url?scp=0027234346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027234346&partnerID=8YFLogxK

U2 - 10.1006/gyno.1993.1195

DO - 10.1006/gyno.1993.1195

M3 - Article

C2 - 8375737

AN - SCOPUS:0027234346

VL - 50

SP - 215

EP - 220

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -